Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Diseases: Disruptive, Commercially Risky, But GSK Has A Solution

Executive Summary

GlaxoSmithKline PLC has offered up its new Maryland vaccine research and development center, and its scientists, under the company's proposal to establish a global collaboration for the pursuit of products that are commercially risky, but necessary to address emerging infectious diseases, before a public health crisis strikes.

You may also be interested in...

Playing the Long Game, Partnerships Required For Emerging Infectious Diseases

Bringing drugs and vaccines for emerging infectious diseases to the marketplace requires playing the long game and collaborations if efforts are going to be successful.

GSK/NIH 'SAM' Strategy May Reap Benefits Beyond Zika

GlaxoSmithKline PLC and the National Institute of Allergy and Infectious Diseases have entered into a partnership to develop a Zika vaccine based on the company's self-amplifying mRNA technology – a collaboration that could yield biomedical research and development benefits far beyond the current epidemic.

Fauci: Borrowed Cash Won't Carry Zika Efficacy Trials

Cash borrowed from various US government programs, including the Ebola response, is enough to get at least two Phase I Zika vaccine trials underway, but those funds won't carry the efficacy studies – the preparations of which must get off the ground next month. So Congress needs to allocate new dollars within the next few weeks or the Phase II trials will be in jeopardy, Anthony Fauci, the nation's top infectious disease official, told Scrip.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts